Joachim Rudolph

Joachim Rudolph

Auto-generated profile, based on publicly available information

Joachim Rudolph

Department of Discovery Chemistry, Genentech, Inc., South San Francisco, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2007 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JRJoachim Rudolph
Joachim Rudolph
WEWilliam P. Esler
William P. Esler
SOStephen O'COnnor
Stephen O'COnnor
PCPhilip D. G. Coish
Philip D. G. Coish
PWPhilip L. Wickens
Philip L. Wickens
WBWilliam H. Bullock
William H. Bullock

23 April 2015 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
COChristy C Ong
Christy C Ong
SGSarah Gierke
Sarah Gierke
CPCameron Pitt
Cameron Pitt
MSMeredith Sagolla
Meredith Sagolla
CCChristine K Cheng
Christine K Cheng
KHKlaus P Hoeflich
Klaus P Hoeflich
Introduction: Breast cancer, the most common cause of cancer-related deaths worldwide among women, is a molecularly and clinically heterogeneous disease. Extensive genetic and epigenetic profiling of breast tumors has recently revealed novel putative driver genes, including p21-activated kinase (PAK)1. PAK1 is a serine/threonine kinase downstream of small GTP-binding proteins, Rac1 and Cdc42, and is an integral component of growth factor signaling networks and cellular functions fundamental to tumorigenesis. Methods: PAK1 dysregulation (copy number gain, mRNA and protein expression) was evaluated in two cohorts of breast cancer tissues (n = 980 and 1,108). A novel small molecule inhibitor, FRAX1036, and RNA interference were used to examine PAK1 loss of function and combination with docetaxel in vitro. Mechanism of action for the therapeutic combination, both cellular and molecular, was assessed via time-lapse microscopy and immunoblotting. Results: We demonstrate that focal genomic amplification and overexpression of PAK1 are associated with poor clinical outcome in the luminal subtype of breast cancer (P = 1.29 × 10−4 and P = 0.015, respectively). Given the role for PAK1 in regulating cytoskeletal organization, we hypothesized that combination of PAK1 inhibition with taxane treatment could be combined to further interfere with microtubule dynamics and cell survival. Consistent with this, administration of docetaxel with either a novel small molecule inhibitor of group I PAKs, FRAX1036, or PAK1 small interfering RNA oligonucleotides dramatically altered signaling to cytoskeletal-associated proteins, such as stathmin, and induced microtubule disorganization and cellular apoptosis. Live-cell imaging revealed that the duration of mitotic arrest mediated by docetaxel was significantly reduced in the presence of FRAX1036, and this was associated with increased kinetics of apoptosis. Conclusions: Taken together, these findings further support PAK1 as a potential target in breast cancer and suggest combination with taxanes as a viable strategy to increase anti-tumor efficacy.

3 December 2014 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JRJoachim Rudolph
Joachim Rudolph
JCJames J. Crawford
James J. Crawford
KHKlaus P. Hoeflich
Klaus P. Hoeflich
WWWeiru Wang
Weiru Wang

5 July 2023 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
IHIngo V. Hartung
Ingo V. Hartung
JRJoachim Rudolph
Joachim Rudolph
MMMary M. Mader
Mary M. Mader
MMMonique Mulder
Monique Mulder
PWPaul Workman
Paul Workman
Within druggable target space, new small-molecule modalities, particularly covalent inhibitors and targeted degraders, have expanded the repertoire of medicinal chemists. Molecules with such modes of action have a large potential not only as drugs but also as chemical probes. Criteria have previously been established to describe the potency, selectivity, and properties of small-molecule probes that are qualified to enable the interrogation and validation of drug targets. These definitions have been tailored to reversibly acting modulators but fall short in their applicability to other modalities. While initial guidelines have been proposed, we delineate here a full set of criteria for the characterization of covalent, irreversible inhibitors as well as heterobifunctional degraders ("proteolysis-targeting chimeras", or PROTACs) and molecular glue degraders. We propose modified potency and selectivity criteria compared to those for reversible inhibitors. We discuss their relevance and highlight examples of suitable probe and pathfinder compounds.

4 February 2014 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SSSteven T. Staben
Steven T. Staben
JFJianwen A. Feng
Jianwen A. Feng
KLKaren Lyle
Karen Lyle
MBMarcia Belvin
Marcia Belvin
JBJason Boggs
Jason Boggs
KHKlaus P. Hoeflich
Klaus P. Hoeflich

14 December 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
EFElena Ferri
Elena Ferri
ATAdrien Le Thomas
Adrien Le Thomas
HWHeidi Ackerly Wallweber
Heidi Ackerly Wallweber
EDEric S. Day
Eric S. Day
BWBenjamin T. Walters
Benjamin T. Walters
WWWeiru Wang
Weiru Wang
Inositol-Requiring Enzyme 1 (IRE1) is an essential component of the Unfolded Protein Response. IRE1 spans the endoplasmic reticulum membrane, comprising a sensory lumenal domain, and tandem kinase and endoribonuclease (RNase) cytoplasmic domains. Excess unfolded proteins in the ER lumen induce dimerization and oligomerization of IRE1, triggering kinase trans-autophosphorylation and RNase activation. Known ATP-competitive small-molecule IRE1 kinase inhibitors either allosterically disrupt or stabilize the active dimeric unit, accordingly inhibiting or stimulating RNase activity. Previous allosteric RNase activators display poor selectivity and/or weak cellular activity. In this study, we describe a class of ATP-competitive RNase activators possessing high selectivity and strong cellular activity. This class of activators binds IRE1 in the kinase front pocket, leading to a distinct conformation of the activation loop. Our findings reveal exquisitely precise interdomain regulation within IRE1, advancing the mechanistic understanding of this important enzyme and its investigation as a potential small-molecule therapeutic target.